PMID- 7742263
OWN - NLM
STAT- MEDLINE
DCOM- 19950615
LR  - 20190913
IS  - 0920-3206 (Print)
IS  - 0920-3206 (Linking)
VI  - 8
IP  - 6
DP  - 1994 Dec
TI  - Efficacy and tolerability of felodipine ER and diltiazem SR as monotherapy in 
      primary hypertension: a double-blind randomized study.
PG  - 845-9
AB  - PURPOSE: Efficacy, tolerability, and optimal doses of felodipine ER (FER) and 
      diltiazem SR (DSR), given as monotherapy, were evaluated in patients with mild or 
      moderate primary hypertension. METHODS: This was a multicenter, double-blind, 
      parallel-group study of 98 hypertensive patients. Following a 4 weeks placebo 
      run-in period, patients were randomized to either FER 5 mg once daily (qd) or DSR 
      90 mg twice daily (bid). If supine DBP was > 90 mmHg after 2 and 4 weeks 
      treatment, the dose was increased to 10 mg FER qd or 120 mg DSR bid plus 20 mg 
      FER qd or 180 mg DSR bid, respectively. The double-blind treatment lasted 8 
      weeks. RESULTS: After 8 weeks FER treatment 70% of the patients responded (DBP < 
      or = 90 mmHg or DBP decrease > or = 10 mmHg) and 50% became normotensive (DBP < 
      or = 90 mmHg); the corresponding figures for DSR were 63% and 37%, respectively. 
      No statistical significant differences in BP reduction and HR were found between 
      the two compounds. HR did not change during the study. Seven patients 
      discontinued due to adverse events (AEs). Five patients received FER and two 
      patients received DSR. The AEs were similar in the two groups and generally mild. 
      CONCLUSIONS: At the highest dose levels of FER and DSR, no further BP reduction 
      was observed, but there was a tendency to report more AEs. Both FER and DSR can 
      be used as first-line therapy in hypertension.
FAU - Thulin, T
AU  - Thulin T
AD  - Department of Medicine, University Hospital, Lund, Sweden.
FAU - Almkvist, H
AU  - Almkvist H
FAU - Berglund, L
AU  - Berglund L
FAU - Bjornsson, T
AU  - Bjornsson T
FAU - Fagher, B
AU  - Fagher B
FAU - Henningsen, N
AU  - Henningsen N
FAU - Honkavaara, M
AU  - Honkavaara M
FAU - Naukkarinen, V
AU  - Naukkarinen V
FAU - Nordenstrom, P
AU  - Nordenstrom P
FAU - Sillanpaa, J
AU  - Sillanpaa J
AU  - et al.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - United States
TA  - Cardiovasc Drugs Ther
JT  - Cardiovascular drugs and therapy
JID - 8712220
RN  - 0 (Delayed-Action Preparations)
RN  - EE92BBP03H (Diltiazem)
RN  - OL961R6O2C (Felodipine)
SB  - IM
MH  - Blood Pressure/drug effects
MH  - Delayed-Action Preparations
MH  - Diltiazem/administration & dosage/adverse effects/*therapeutic use
MH  - Double-Blind Method
MH  - Felodipine/administration & dosage/adverse effects/*therapeutic use
MH  - Female
MH  - Heart Rate/drug effects
MH  - Humans
MH  - Hypertension/blood/*drug therapy/physiopathology
MH  - Male
MH  - Middle Aged
EDAT- 1994/12/01 00:00
MHDA- 1994/12/01 00:01
CRDT- 1994/12/01 00:00
PHST- 1994/12/01 00:00 [pubmed]
PHST- 1994/12/01 00:01 [medline]
PHST- 1994/12/01 00:00 [entrez]
AID - 10.1007/BF00877403 [doi]
PST - ppublish
SO  - Cardiovasc Drugs Ther. 1994 Dec;8(6):845-9. doi: 10.1007/BF00877403.